QNCX Quince: Accounting Value per Share

Graphic logo of Quince Therapeutics, Inc. (QNCX)

The aggregate book value per share correlates with the image of Quince Therapeutics (QNCX) as an innovator in the therapy of rare pathologies, while the value of -34.45 describes the current level. The business foundation is based on compliance with bioethics and environmental ESG standards. The technical base relies on the pristine condition of the laboratories, where equipment for processing cell batches is strictly calibrated.

Quince (QNCX): Share Book Value from 04/28/2023 to 10/12/2026

Quince Therapeutics Inc - analytical breakdowns and key metrics (QNCX)

- price and consensus price forecast:
Stock Price Quince|QNCX - Consensus Target
- market capitalization data:
Market Valuation Quince Therapeutics, Inc.|QNCX - Business Value
- book capitalization data:
Net Assets per Single Share Quince Therapeutics|QNCX - Net Asset Value|Market Capitalization to Book Value Ratio quincetx.com|QNCX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Quince Therapeutics|QNCX - Long-Term Debt to Capital|Short-Term Debt to Equity Quince|QNCX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Quince Therapeutics, Inc.|QNCX - Company Long-Term Liabilities|Company Short-Term Debts Quince Therapeutics
Fundamental company valuation:quincetx.com - QNCX
Manufactured products of Quince

The development of the AOD platform and the clinical successes of Quince Therapeutics (QNCX) in treating metabolic syndromes directly impact asset capitalization, as reflected by the book value per share metric. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares, allowing investors to assess the real value of their ownership stake in the business net of all debt.

Competitors of Quince Therapeutics (QNCX)

ASND: Book Value per Share|Madrigal Corp (MDGL) - Accounting Value per Share|Accounting Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS